Cytomegalovirus surface protein complex for use in vaccines and as a drug target

摘要

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

主权项

1. An antibody that specifically binds a cytomegalovirus (CMV) protein complex comprising pUL130 and a CMV protein selected from the group consisting of gH, gL, pUL128 and pUL131, said antibody is selected from the group consisting of:
(a) an antibody secreted by hybridoma cell line ATCC Accession No. PTA-8472; (b) an antibody comprising a heavy chain of a monoclonal antibody secreted by hybridoma cell line ATCC Accession No. PTA-8472; (c) an antibody comprising a light chain of a monoclonal antibody secreted by hybridoma cell line ATCC Accession No. PTA-8472; (d) an antibody comprising the six CDRs from the heavy chain and the light chain of a monoclonal antibody secreted by hybridoma cell line ATCC Accession No. PTA-8472; (e) an antibody fragment comprising a heavy chain or a light chain of a monoclonal antibody secreted by hybridoma cell line ATCC Accession No. PTA-8472; and (f) an antibody fragment comprising the six CDRs from the heavy chain and the light chain of a monoclonal antibody secreted by hybridoma cell line ATCC Accession No. PTA-8472, wherein the antibody reduces CMV binding to a cell.